Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE1-TBHSP70
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Intraperitoneal, Oral
01
Overview
MAGE1-TBHSP70 is a recombinant protein vaccine construct designed for cancer immunotherapy. It consists of the MAGE1 (Melanoma-Associated Antigen 1) tumor antigen fused to a truncated bacterial heat shock protein 70 (TBHSP70) derived from *Mycobacterium tuberculosis*. The TBHSP70 component acts as a molecular chaperone and potent adjuvant, enhancing the processing and presentation of the MAGE1 antigen to stimulate cytotoxic T lymphocyte (CTL)-mediated immune responses. This vaccine targets MAGE-expressing tumor cells, which are found in various cancers including melanoma, hepatocellular carcinoma, and pulmonary carcinoma. Research on this construct was primarily academic, supported by Chinese national science programs, and served as a precursor to the multivalent MAGE1-MAGE3-TBHSP70 vaccine.
- Other names
- MAGE1/TBHSP70MAGE1-TBHSP70 recombinant protein vaccineMAGE-1-TBHSP70 recombinant protein vaccineMAGE 1-TBHSP70 recombinant protein vaccineMAGE1-TBHSP70 fusion proteinMAGE-1-TBHSP70 fusion proteinMAGE 1-TBHSP70 fusion protein
02
Targets
MAGEA1 (Melanoma-associated antigen 1)
Beyond the preview
Go deeper on MAGE1-TBHSP70.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE1-TBHSP70.